Tonix Pharmaceuticals (TNXP) Earns Daily News Impact Rating of 0.17
News articles about Tonix Pharmaceuticals (NASDAQ:TNXP) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.7517326250488 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several analysts recently weighed in on the company. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. ValuEngine downgraded Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Dawson James restated a “buy” rating and issued a $9.00 price target on shares of Tonix Pharmaceuticals in a research note on Wednesday, August 23rd. Drexel Hamilton assumed coverage on Tonix Pharmaceuticals in a research note on Tuesday, August 22nd. They issued a “buy” rating on the stock. Finally, Roth Capital upgraded Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Friday, August 18th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $8.33.
Shares of Tonix Pharmaceuticals (NASDAQ TNXP) traded up $0.04 on Friday, reaching $3.82. The company’s stock had a trading volume of 45,033 shares, compared to its average volume of 65,277. Tonix Pharmaceuticals has a 1-year low of $2.85 and a 1-year high of $9.40.
TRADEMARK VIOLATION WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/10/tonix-pharmaceuticals-tnxp-earns-daily-news-impact-rating-of-0-17.html.
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.